Parkinson's Disease Treatment

Parkinson's Disease Treatment

Global Parkinson's Disease Treatment Market to Reach $8 Billion by 2030
The global market for Parkinson's Disease Treatment estimated at US$5.7 Billion in the year 2023, is expected to reach US$8 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Levodopa / Carbidopa Drug Class, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Dopamine Receptor Agonists Drug Class segment is estimated at 4.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.5 Billion, While China is Forecast to Grow at 7.6% CAGR
The Parkinson's Disease Treatment market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 7.6% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 4.6% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 2.8% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.1 Billion by the year 2030.

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.Select Competitors (Total 42 Featured) -
  • AbbVie
  • Acadia
  • Boehringer Ingelheim
  • Dr. Reddy’s
  • GSK
  • Impax
  • Lundbeck
  • Merck
  • Novartis
  • Sun Pharma
  • Teva
  • UCB
  • US WorldMeds
  • Valeant Pharmaceuticals
  • Wockhardt
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Parkinson's Disease Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Parkinson's Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Parkinson's Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Levodopa / Carbidopa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Levodopa / Carbidopa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Levodopa / Carbidopa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Dopamine Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Dopamine Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Dopamine Receptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for MAO-Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for MAO-Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for MAO-Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for COMT-inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for COMT-inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for COMT-inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 26: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 27: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 28: World Parkinson's Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
JAPAN
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
CHINA
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
EUROPE
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Parkinson's Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Parkinson's Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
FRANCE
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: France 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
GERMANY
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Germany 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Italy 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
UNITED KINGDOM
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: UK 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Spain 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Russia 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Rest of Europe 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Parkinson's Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Parkinson's Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
AUSTRALIA
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Australia 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
INDIA
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: India Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: India 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: South Korea 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
LATIN AMERICA
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Parkinson's Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Parkinson's Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Latin America 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Argentina 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Brazil 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Mexico 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Rest of Latin America 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
MIDDLE EAST
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Parkinson's Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Parkinson's Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Middle East 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Iran 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Israel 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Saudi Arabia 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: UAE 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Rest of Middle East 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
AFRICA
Parkinson's Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Parkinson's Disease Treatment by Drug Class - Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Parkinson's Disease Treatment by Drug Class - Percentage Breakdown of Value Sales for Levodopa / Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics and Other Drug Classes for the Years 2014, 2024 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Parkinson's Disease Treatment by End-Use - Hospitals and Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Africa 16-Year Perspective for Parkinson's Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals and Clinics for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings